Osteoporosis: Drugs That Stop Bone Being Lost
Bone looks solid and permanent, but it's actually a living tissue in constant renovation — old bone removed, new bone laid down. Osteoporosis is what happens when removal outpaces replacement and bones become fragile. Most osteoporosis drugs work by one simple idea: slow down the demolition crew. Understanding that turns a confusing list of drugs into a single clear strategy.
Bone is never static. Two teams of cells work on it constantly: osteoclasts break old bone DOWN (resorption), and osteoblasts build new bone UP (formation). In a healthy adult these balance out. But with age — and especially after menopause, when the loss of estrogen removes a brake on the demolition team — resorption starts to outpace formation. Bone is lost faster than it's replaced, the internal structure thins, and bones become fragile and prone to fracture from minor falls. That's osteoporosis. Because the core problem is too much breakdown, the core treatment is obvious: put the brakes back on the osteoclasts.
The main drugs: slowing bone breakdown
Bisphosphonates and denosumab both stop the osteoclasts. The first-line drugs are the bisphosphonates (alendronate, risedronate, zoledronate). They bind into the bone and are taken up by osteoclasts, whom they disable — so bone breakdown slows and the bone gradually strengthens. They're effective and cheap, but their oral form has a strict administration ritual that follows from two facts: they're poorly absorbed and can irritate the food-pipe. So the classic rule is to take the tablet first thing in the morning with a full glass of water, on a completely empty stomach, and then stay upright (sitting or standing) for 30–60 minutes and not eat — maximising absorption and protecting the oesophagus. Two rare but important long-term side effects are worth knowing: osteonecrosis of the jaw (which is why dental health is checked before long courses) and unusual 'atypical' femur fractures. The alternative, denosumab, is a twice-yearly injection of an antibody that blocks the signal (RANKL) osteoclasts need to work; it's very effective, but has a crucial catch — if it's stopped, bone loss rebounds rapidly, so it can't simply be discontinued without a plan. Different molecules, same core aim: stop the osteoclasts.
The foundations: calcium, vitamin D, and the others
No bone drug works well on a shaky foundation, so adequate calcium and vitamin D are the bedrock of every osteoporosis regimen — you can't build or maintain bone without the raw material (calcium) and the hormone that lets you absorb it (vitamin D, the subject of the next article). Beyond the mainstays, a few other agents fill specific roles. Because estrogen naturally restrains bone breakdown, HRT and the estrogen-like drug raloxifene (a 'SERM') can protect bone, though they're chosen for particular situations. And for severe osteoporosis, there's a different and striking strategy: instead of slowing breakdown, teriparatide actively BUILDS new bone. It's a form of parathyroid hormone, and here's the fascinating twist — although continuously high parathyroid hormone strips calcium from bone, giving it as brief daily pulses does the opposite and stimulates bone formation. It's a reminder that in endocrinology, the pattern of a hormone signal (steady versus pulsed) can flip its effect entirely.
- Bone is constantly remodelled: osteoclasts break down, osteoblasts build up.
- Osteoporosis = breakdown outpaces formation (accelerated after menopause).
- Bisphosphonates (alendronate) disable osteoclasts — first-line; strict empty-stomach, stay-upright dosing.
- Rare bisphosphonate risks: jaw osteonecrosis, atypical femur fracture. Denosumab: rebound if stopped.
- Calcium + vitamin D underpin everything; teriparatide (pulsed PTH) BUILDS bone in severe disease.
The most beautiful idea in bone pharmacology is teriparatide's paradox, and it captures something deep about hormones. Parathyroid hormone's everyday job is to raise blood calcium, partly by pulling it out of bone — so you'd think giving PTH would weaken bones. And it does, IF the level stays continuously high. But give the very same hormone as a short daily spike, and it flips: the brief pulse stimulates the bone-building osteoblasts more than the bone-dissolving osteoclasts, so bone is actually built up. Continuous signal, bone lost; pulsed signal, bone gained. It's proof that with hormones, it's not only how much you give but the rhythm in which you give it that determines the effect — one of endocrinology's most elegant lessons.
- Taking an oral bisphosphonate with food or lying down — poor absorption and oesophageal irritation.
- Stopping denosumab without a follow-on plan — rapid rebound bone loss/fractures.
- Prescribing bone drugs without ensuring adequate calcium and vitamin D.
- Ignoring dental check before long bisphosphonate courses (jaw osteonecrosis risk).
How do bisphosphonates strengthen bone in osteoporosis?
- Osteoporosis = bone breakdown outpaces formation (esp. post-menopause).
- Bisphosphonates (first-line) and denosumab slow the osteoclasts; strict dosing/rebound cautions.
- Calcium + vitamin D underpin all treatment; teriparatide (pulsed PTH) builds bone.
- Watch jaw osteonecrosis with bisphosphonates; don't stop denosumab without a plan.
- Katzung BG. Basic & Clinical Pharmacology — Agents That Affect Bone Mineral Homeostasis.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Bone mineral homeostasis.
- NOGG / Endocrine Society — Osteoporosis management guidelines.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Drugs affecting bone.
